Selecta adds expertise to develop nanoparticle malaria vaccine for US government
This article was originally published in Scrip
Executive Summary
Selecta Biosciences, a company with a platform for specifically engineered vaccines, will be part of a collaborative effort, backed by the US government, to develop a targeted synthetic nanoparticle vaccine against malaria.